Leishmaniasis is a parasitic disease, endemic to Africa, Asia, and South America due to inadequate access to medication and underreporting of leishmaniasis cases. Leishmaniasis has two forms: cutaneous and visceral. The fight against leishmaniasis has been greatly affected by the coronavirus disease 2019 (COVID-19) pandemic that impacted resource distribution and access to medication. Continuous effort in vaccine development and affordable therapeutics are necessary to eliminate leishmaniasis in low-income countries. Further research is necessary to determine molecular drug resistance markers in leishmaniasis patients. In this analysis, we focus on the effect of COVID-19 on leishmaniasis in Africa.
BT - Annals of Medicine and Surgery DO - 10.1016/j.amsu.2022.104263 LA - eng N2 -Leishmaniasis is a parasitic disease, endemic to Africa, Asia, and South America due to inadequate access to medication and underreporting of leishmaniasis cases. Leishmaniasis has two forms: cutaneous and visceral. The fight against leishmaniasis has been greatly affected by the coronavirus disease 2019 (COVID-19) pandemic that impacted resource distribution and access to medication. Continuous effort in vaccine development and affordable therapeutics are necessary to eliminate leishmaniasis in low-income countries. Further research is necessary to determine molecular drug resistance markers in leishmaniasis patients. In this analysis, we focus on the effect of COVID-19 on leishmaniasis in Africa.
PB - Elsevier BV PY - 2022 EP - 104263 T2 - Annals of Medicine and Surgery TI - Leishmaniasis control in the light of the COVID-19 pandemic in Africa UR - https://www.sciencedirect.com/science/article/pii/S2049080122010238/pdfft?md5=5e1709834eb660d3fccbd2603514a82b&pid=1-s2.0-S2049080122010238-main.pdf SN - 2049-0801 ER -